Progressive Payments to acquire available-for-sale debt securities increased by 71.9% to $14.71B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 23.2%, from $11.94B to $14.71B. Over 4 years (FY 2021 to FY 2025), Payments to acquire available-for-sale debt securities shows an upward trend with a 10.6% CAGR.
An increase indicates the company is actively managing its cash reserves by investing in liquid assets, while a decrease may suggest a shift toward other uses of capital.
This metric tracks the cash outflow used to purchase available-for-sale debt securities as part of the company's treasur...
Standard treasury management metric; common for cash-rich biotech firms managing large balance sheets.
is_jpm_payments_to_acquire_afs_securities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.94B | $6.86B | $7.96B | $11.45B | $2.88B | $4.34B | $7.84B | $6.12B | $6.25B | $6.59B | $6.82B | $13.29B | $11.24B | $11.30B | $11.94B | $17.32B | $9.03B | $8.56B | $14.71B |
| QoQ Change | — | -13.7% | +16.0% | +44.0% | -74.9% | +50.8% | +80.6% | -21.9% | +2.2% | +5.3% | +3.6% | +94.8% | -15.4% | +0.5% | +5.7% | +45.1% | -47.9% | -5.2% | +71.9% |
| YoY Change | — | — | — | — | -63.8% | -36.7% | -1.5% | -46.6% | +117.1% | +51.7% | -13.0% | +117.1% | +79.9% | +71.6% | +75.1% | +30.4% | -19.7% | -24.3% | +23.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.